Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding (Weighted Average) (2019 - 2025)

Lyell Immunopharma's Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $18.3 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 42.55% year-over-year to $18.3 million; the TTM value through Sep 2025 reached $18.3 million, up 42.55%, while the annual FY2024 figure was $261.5 million, 4.18% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $18.3 million at Lyell Immunopharma, up from $14.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $295.1 million in Q1 2025 and bottomed at $12.7 million in Q2 2024.
  • The 5-year median for Shares Outstanding (Weighted Average) is $245.3 million (2022), against an average of $165.2 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) surged 796755.45% in 2021 before it tumbled 94.9% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $135.9 million in 2021, then surged by 81.79% to $247.1 million in 2022, then rose by 1.58% to $251.0 million in 2023, then rose by 4.18% to $261.5 million in 2024, then plummeted by 93.01% to $18.3 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Shares Outstanding (Weighted Average) are $18.3 million (Q3 2025), $14.8 million (Q2 2025), and $295.1 million (Q1 2025).